[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"essential-thrombocythaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:essential-thrombocythaemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100576510","phase-2-a-phase-2-study-to-assess-stp938-dencatistat-as-a-monotherapy-in-adults-with-high-risk-essential-thrombocythaemia---the-vectra-trial-100576510",false,"NCT06786234","A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial","An Open-Label, Phase 2 Study to Evaluate Safety, Tolerability & Preliminary Activity of the CTPS1 Inhibitor STP938 in Adult Subjects With High Risk Essential Thrombocythaemia Who Are Resistant to or Intolerant of Hydroxycarbamide Therapy","Key Inclusion Criteria:\n\n* Adults aged 18 years or older\n* A confirmed diagnosis of ET according to World Health Organisation (WHO) or British Society for Haematology (BSH) criteria.\n* Meeting criteria for high risk ET.\n* Raised platelet count (\\>600 x109\u002FL) requiring cytoreductive therapy.\n* Neutrophil count \\>1.0 x109\u002FL.\n* Either intolerant of or resistant to hydroxycarbamide having met any one of the criteria at any point in their disease whilst receiving hydroxycarbamide.\n* Adequate hepatic function.\n* Adequate blood coagulation parameters.\n* Eastern Cooperative Oncology Group (ECOG) status of 0-2.\n\nKey Exclusion Criteria:\n\n* Subjects currently or recently receiving cytoreductive therapy for the treatment of essential thrombocythaemia (wash out periods apply).\n* Subjects who have received any investigational agents for the treatment of essential thrombocythaemia within 4 weeks before enrolment or less than 5 half-lives since completion of prior therapy, whichever is shorter.\n* Proven or suspected transformation to polycythaemia vera, myelofibrosis, myelodysplasia, acute myeloid leukaemia or another myeloid neoplasm.\n* Known malabsorption syndrome or other condition that may impair absorption of study medication (e.g. gastrectomy).\n* Previous splenectomy.\n* Any uncontrolled intercurrent illness.\n* Immunocompromised subjects with increased risk of opportunistic infections.\n* Known active or chronic hepatitis B or active hepatitis C virus (HCV) infection.\n* Pregnant females, breastfeeding females, and women of child bearing age or males not willing to comply with contraceptive requirements.\n* Known hypersensitivity to any of the excipients used in the formulation of the study drug.\n* Corrected QT interval \\>470 msec based on averaged triplicate electrocardiogram (ECG) readings at the Screening Visit using the QT interval corrected for heart rate using Fridericia's method (QTcF).","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this clinical trial is to learn if the drug STP938 works to treat adults with high risk essential thrombocythaemia (ET) who are resistant to, or intolerant of, hydroxycarbamide (also known as hydroxyurea) therapy. The trial will also learn about the safety of STP938. The main questions the trial aims to answer are:\n\n* Does STP938 control platelet counts\n* Does STP938 control platelet counts without inducing unwanted side effects\n\nParticipants will:\n\n* Take STP938 every day for up to 12 months.\n* Visit the clinic once every week for the first month, then every 2 weeks for checkups and tests.\n* Complete a questionnaire about symptoms once a month.",[26],"Essential Thrombocythaemia",[28,29,30,31,32],"Essential Thrombocythemia","High risk","Resistant to or Intolerant of Hydroxycarbamide Therapy","Resistant to or Intolerant of Hydroxyurea Therapy","Oral therapy","RECRUITING","2026-06-13",{"date":36,"type":37},"2026-06-16","ACTUAL",{"date":39,"type":37},"2025-06-18",{"date":41,"type":20},"2028-09-30",{"name":43,"class":44},"Step Pharma, SAS","INDUSTRY",14,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100587075","prevalence-of-germline-gene-mutations-in-patients-with-myeloproliferative-neoplasms-with-family-history-100587075","NCT06923670","Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History","Inclusion Criteria:\n\n\\*Patients \\>18 years\n\n* Diagnosis of MPN (Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis) confirmed according to ICC 2022 criteria\n* Familiarity for myeloid neoplasia: at least one first or second degree relative affected by myeloid neoplasia (probands) OR presence of matching criteria with a proband (controls). Each center will be able to contribute with its own available patients\u002Frelatives, providing the clinical-laboratory data required by the study.\n\n  * Signing of informed consent according to ICH\u002FEU\u002FGCP and local national laws (if applicable)\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years Patients with other hematological diagnoses; • Lack of informed consen",{"count":53,"type":20},496,[55],"NA","Philadelphia-negative myeloproliferative neoplasms (MPNs) occur sporadically and are due to somatic mutations in the JAK2 (Janus kinase 2), CALR (calreticulin) and MPL (thrombopoietin receptor) genes. However, data from epidemiological and family studies clearly highlight a heritable component that influences the risk of developing MPN and potentially contributes to the observed phenotypic pleiotropy. Genome-wide association studies in MPN familial clusters have identified a number of germline genetic variants associated with an increased risk of developing MPN. The strongest association discovered so far is the presence of the JAK2 46\u002F1 haplotype and, subsequently, several studies have found additional variants in other genes, particularly in the TERT gene.\n\nThe aim of the study would be to investigate the presence of germline mutations in MPN patients selected on the basis of a family history of myeloid neoplasms through the analysis of both already recognized genes and other potentially implicated ones.",[58,26,59],"Polycythemia Vera","Myelofibrosis","NOT_YET_RECRUITING","2025-05-14",{"date":63,"type":37},"2025-05-15",{"date":65,"type":20},"2025-05-21",{"date":67,"type":20},"2028-05-01",{"name":69,"class":70},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER"]